Therefore, we aimed to characterize the proteome of MDM2-amplified esophageal adenocarcinomas in comparison to non-amplified tumors, identifying altered pathways as potential additional therapeutic targets. The gene discussed is MDM2; the disease is esophageal adenocarcinoma.